https://biotechmorning.com/news/lilly-100m-innocare-beijing-deal Biotech Morning en 2026-09-24T14:20:23.640Z Lilly's $100M Bet on a Beijing Biotech Isn't Supposed to Happen Right Now https://biotechmorning.com/news/europe-pharma-ceos-sos-biotech-decline Biotech Morning en 2026-09-24T14:19:41.622Z Europe's Biggest Pharma Companies Just Sent an SOS https://biotechmorning.com/news/sefaxersen-igan-phase-3-crowded-market Biotech Morning en 2026-09-24T14:18:59.875Z The Kidney Drug That Just Crashed Biotech's Most Crowded Party https://biotechmorning.com/news/roche-2-billion-atavistik-bio-cvrm-deal Biotech Morning en 2026-09-24T14:18:13.450Z Roche Just Bet $2 Billion on a Company Most People Haven't Heard Of https://biotechmorning.com/news/merck-remigromig-brunello-trial-dme Biotech Morning en 2026-09-24T14:17:24.399Z Merck Just Found a Way to Fix Leaky Blood Vessels in the Eye https://biotechmorning.com/news/galleri-blood-test-fda-panel-vote Biotech Morning en 2026-09-24T14:16:40.024Z A Blood Test That Catches 50+ Cancers Just Cleared Its Biggest Hurdle https://biotechmorning.com/news/eu-gene-edited-crops-regulation-shift Biotech Morning en 2026-09-24T14:15:53.766Z Europe Just Cracked Open the Door to Gene-Edited Crops https://biotechmorning.com/news/flagship-pioneering-pentagon-biodefense-contract Biotech Morning en 2026-09-24T14:15:12.133Z Flagship Pioneering Just Became a Defense Contractor https://biotechmorning.com/news/enveda-311m-series-e-plant-ai-drug-discovery Biotech Morning en 2026-09-24T14:14:29.658Z The $311M Bet That Plants Are Smarter Than Pharma Chemists https://biotechmorning.com/news/kyverna-car-t-miv-cel-autoimmune-one-year-data Biotech Morning en 2026-09-24T14:13:40.399Z Kyverna's CAR-T Therapy Just Did Something Its Rivals Can't https://biotechmorning.com/news/fda-nominee-heidi-overton-senate-confirmation-hearing Biotech Morning en 2026-09-24T14:12:53.404Z The FDA's Next Boss Has Never Run Anything Like the FDA https://biotechmorning.com/news/merck-winrevair-hyperion-pah-label-update Biotech Morning en 2026-09-23T14:17:08.169Z Merck's PAH Drug Just Put Up a Number That's Hard to Ignore https://biotechmorning.com/news/sjogrens-disease-amgen-dazodalibep-phase-3-win Biotech Morning en 2026-09-23T14:16:21.741Z The Disease Nobody Could Treat Just Met Its Match https://biotechmorning.com/news/celldex-barzolvolimab-phase-3-chronic-hives-safety-concerns Biotech Morning en 2026-09-23T14:15:35.770Z Celldex Aced Its Biggest Exam. Wall Street Still Gave It a Failing Grade. https://biotechmorning.com/news/ulefnersen-fus-als-phase-3-survival-results Biotech Morning en 2026-09-23T14:14:49.656Z The Drug That's Beating One of Medicine's Cruelest Diseases https://biotechmorning.com/news/immunovant-lupus-bet-goes-bust Biotech Morning en 2026-09-23T14:14:06.689Z Immunovant's Lupus Bet Just Went Bust. Now What? https://biotechmorning.com/news/hhs-reduce-animal-testing-drug-development Biotech Morning en 2026-09-23T14:13:22.622Z The U.S. Government Just Told Lab Mice to Start Updating Their Résumés https://biotechmorning.com/news/novartis-boomray-900m-preclinical-radioligand-deal Biotech Morning en 2026-09-23T14:12:38.338Z Novartis Just Paid Up to $900M for a Drug That Doesn't Exist Yet https://biotechmorning.com/news/sarepta-black-box-warning-layoffs-duchenne-3 Biotech Morning en 2026-09-23T14:11:52.901Z Sarepta's Worst Week: A Black Box, 500 Pink Slips, and a $20 Stock https://biotechmorning.com/news/novartis-avidity-second-trial-failure Biotech Morning en 2026-09-23T14:11:05.916Z Novartis Paid $12 Billion for a Platform. Now It's 0-for-2.